Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 48.6
(8.0%)
SEK 48.6
(8.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 134.69 Million SEK | 104.68% |
| 2022 | 65.8 Million SEK | 47.62% |
| 2021 | 44.57 Million SEK | -38.02% |
| 2020 | 71.91 Million SEK | 52.37% |
| 2019 | 47.2 Million SEK | 19.75% |
| 2018 | 39.41 Million SEK | 8.35% |
| 2017 | 36.37 Million SEK | -4.9% |
| 2016 | 38.25 Million SEK | 85.55% |
| 2015 | 20.61 Million SEK | 212.73% |
| 2014 | 6.59 Million SEK | 1529366.36% |
| 2013 | 431.00 SEK | 125.28% |
| 2012 | -1705.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 44.27 Million SEK | 48.6% |
| 2024 Q1 | 29.79 Million SEK | -45.86% |
| 2023 Q2 | 30.95 Million SEK | 27.4% |
| 2023 FY | 136.76 Million SEK | 107.83% |
| 2023 Q4 | 55.03 Million SEK | 63.23% |
| 2023 Q3 | 33.71 Million SEK | 8.94% |
| 2023 Q1 | 24.29 Million SEK | -40.39% |
| 2022 Q2 | -1.75 Million SEK | -109.22% |
| 2022 Q4 | 40.75 Million SEK | 426.17% |
| 2022 FY | 65.8 Million SEK | 47.62% |
| 2022 Q1 | 19.06 Million SEK | 18.46% |
| 2022 Q3 | 7.74 Million SEK | 540.61% |
| 2021 Q4 | 16.09 Million SEK | 7158.33% |
| 2021 FY | 44.57 Million SEK | -38.02% |
| 2021 Q1 | -452 Thousand SEK | -101.7% |
| 2021 Q3 | -228 Thousand SEK | -100.78% |
| 2021 Q2 | 29.16 Million SEK | 6552.21% |
| 2020 Q1 | -1.2 Million SEK | -104.4% |
| 2020 Q3 | 18.58 Million SEK | -33.42% |
| 2020 Q4 | 26.62 Million SEK | 43.25% |
| 2020 FY | 71.91 Million SEK | 52.37% |
| 2020 Q2 | 27.91 Million SEK | 2414.68% |
| 2019 Q4 | 27.42 Million SEK | 149.17% |
| 2019 Q3 | 11 Million SEK | 38.92% |
| 2019 Q2 | 7.92 Million SEK | 752.85% |
| 2019 FY | 47.2 Million SEK | 19.75% |
| 2019 Q1 | 929 Thousand SEK | -96.11% |
| 2018 Q3 | 7.68 Million SEK | 697.43% |
| 2018 Q1 | 9.14 Million SEK | 0.94% |
| 2018 FY | 39.41 Million SEK | 8.35% |
| 2018 Q4 | 23.87 Million SEK | 210.76% |
| 2018 Q2 | -1.28 Million SEK | -114.06% |
| 2017 Q2 | 13.94 Million SEK | 60.68% |
| 2017 Q1 | 8.68 Million SEK | -38.98% |
| 2017 FY | 36.37 Million SEK | -4.9% |
| 2017 Q3 | 4.57 Million SEK | -67.23% |
| 2017 Q4 | 9.05 Million SEK | 98.18% |
| 2016 Q4 | 14.22 Million SEK | 78.95% |
| 2016 Q2 | 10.97 Million SEK | 115.07% |
| 2016 Q1 | 5.1 Million SEK | 5.66% |
| 2016 FY | 38.25 Million SEK | 85.55% |
| 2016 Q3 | 7.94 Million SEK | -27.57% |
| 2015 Q3 | 4.82 Million SEK | -0.14% |
| 2015 Q1 | 4.83 Million SEK | 0.0% |
| 2015 FY | 20.61 Million SEK | 212.73% |
| 2015 Q4 | 4.82 Million SEK | 0.0% |
| 2015 Q2 | 4.83 Million SEK | 0.0% |
| 2014 FY | 6.59 Million SEK | 1529366.36% |
| 2013 FY | 431.00 SEK | 125.28% |
| 2012 FY | -1705.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -248.569% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 58.105% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 62.336% |
| Xintela AB (publ) | 57.31 Million SEK | -135.002% |
| Active Biotech AB (publ) | 44.8 Million SEK | -200.596% |
| Amniotics AB (publ) | 29.07 Million SEK | -363.312% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -819.225% |
| BioArctic AB (publ) | 89.62 Million SEK | -50.283% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 91.105% |
| Camurus AB (publ) | 1.05 Billion SEK | 87.289% |
| Cantargia AB (publ) | 290.01 Million SEK | 53.557% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -515.182% |
| CombiGene AB (publ) | 44.14 Million SEK | -205.123% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 5.8% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -375.508% |
| Genovis AB (publ.) | 88.19 Million SEK | -52.719% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -17.051% |
| Mendus AB (publ) | 129.13 Million SEK | -4.303% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1753.247% |
| Intervacc AB (publ) | 79.78 Million SEK | -68.821% |
| Kancera AB (publ) | 63.07 Million SEK | -113.539% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -2340.551% |
| LIDDS AB (publ) | 27.75 Million SEK | -385.349% |
| Lipum AB (publ) | 37.3 Million SEK | -261.042% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1756.824% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 0.896% |
| NextCell Pharma AB | -576.01 Thousand SEK | 23483.604% |
| OncoZenge AB (publ) | 15.9 Million SEK | -746.866% |
| Saniona AB (publ) | 1.07 Million SEK | -12406.407% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 25.884% |
| Ziccum AB (publ) | 27.87 Million SEK | -383.155% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -721.255% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 56.139% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -215.946% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -661.715% |
| Corline Biomedical AB | 30.16 Million SEK | -346.48% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -132.107% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -61.952% |
| Aptahem AB (publ) | 10.01 Million SEK | -1245.199% |
| Fluicell AB (publ) | 28.61 Million SEK | -370.678% |
| Biovica International AB (publ) | 133.72 Million SEK | -0.727% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -580.616% |
| AcouSort AB (publ) | 25.87 Million SEK | -420.536% |
| Abliva AB (publ) | 27.86 Million SEK | -383.363% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 30.391% |
| 2cureX AB (publ) | 36.51 Million SEK | -268.843% |
| I-Tech AB | 40.14 Million SEK | -235.494% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 84.328% |
| Cyxone AB (publ) | 28.21 Million SEK | -377.401% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -23.157% |
| Biosergen AB | 26.8 Million SEK | -402.421% |
| Nanologica AB (publ) | 69.88 Million SEK | -92.731% |
| SynAct Pharma AB | 224.49 Million SEK | 40.002% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -204.903% |
| BioInvent International AB (publ) | 441.4 Million SEK | 69.485% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -462.296% |
| Alzinova AB (publ) | 36.39 Million SEK | -270.079% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 53.513% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1614.478% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -21.44% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -816.286% |